Blog

Designing better medicines using AI and big data

By its own definition, South By Southwest dedicates itself to helping creatives achieve their goals, and proves that the most unexpected discoveries happen when diverse topics and people come together.

And this is what brought our Benevolent Team to Texas - to share our collective vision of using the power of technology to solve something that truly matters to the world. For us this means tackling the most challenging and devastating diseases that currently have no cure, and we believe our efforts can and will change outcomes for patients.

In this video live from SXSW last month, our team of scientists and AI experts presented a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

At SXSW we used the example of Glioblastoma Multiforme, a very aggressive, currently incurable and most common form of brain cancer. We demonstrated something different and a little unconventional - the creative approach of how our team of BenevolentAI scientists, AI experts, engineers and chemists come together to try and solve such a complicated disease.

AI helps us uncover relationships between diseases and symptoms, drugs and their effect, the patients who respond to treatments and so much more. Relationships that would previously not have been uncovered due to the overwhelming volume of biomedical information and the inherent complexity of biology, diseases and the human body.

It’s too early to say if there will be an effective treatment for Glioblastoma any time soon. But every day, we improve our platform and increase the likelihood of finding a treatment. And we hope to return to SXSW to demonstrate the progress we are making on this devastating disease.

More Posts

You Might Also Like

News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Video
How do we get the next 10 years right? w/ Joanna Shields, CogX
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020